• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

在一个疫苗接种率较低的东欧国家保加利亚,对心血管、肿瘤或慢性肺部疾病患者在 COVID-19 背景下的全国范围分析:2020 年 3 月至 2022 年 4 月。

Nationwide analysis of the impact of COVID-19 in patients with a cardiovascular, oncological or chronic pulmonary disease in the context of an Eastern European country with a low vaccination rate, Bulgaria: March 2020-April 2022.

机构信息

Medical University Sofia, Sofia, Bulgaria

Department of Medical Oncology, Medical University of Sofia, Sofia, Bulgaria.

出版信息

BMJ Open. 2023 Aug 2;13(8):e068431. doi: 10.1136/bmjopen-2022-068431.

DOI:10.1136/bmjopen-2022-068431
PMID:37532478
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC10401219/
Abstract

OBJECTIVE

This study focused on Bulgarian patient cohorts harbouring a single documented chronic comorbidity-cardiovascular pathology, an oncological disease or a chronic pulmonary diseases (CPD) comparing the outcomes in fully vaccinated and non-vaccinated populations classified by sex and age groups in ambulatory, hospital and intensive care unit (ICU) settings at the national level.

DESIGN

Retrospective analysis SETTINGS, PARTICIPANTS AND OUTCOME MEASURES: In total, 1 126 946 patients with confirmed COVID-19, on a national level, were retrospectively analysed between March 2020 and April 2022, using data from the Ministry of Health's United Information Portal, launched in March 2020.

RESULTS

Of all the confirmed 247 441 hospitalised cases of COVID-19, 67 723 (27.3%) had documented cardiovascular disease (CVD), 2140 (0.9%) had confirmed solid malignancy (regardless of stage) and 3243 (1.3%) had established CPD as their only chronic pathology. The number of cumulative deaths in each subgroup was 10 165 (in-hospital=5812 and ICU=4353); 4.0% vaccinated (410/10 165, p<0.001), 344 (in-hospital=196 and ICU=148), 4.9% vaccinated (17/344, p<0.001), 494 (in-hospital=287 and ICU=207) and 5.2% vaccinated (26/494, p<0.001), respectively. Statistical significance (p<0.001) was obtained in favour of reduced ambulatory, hospitalisation and both in-hospital and ICU-related mortality in the vaccinated cohorts, and BNT162b2 was the most effective at preventing mortality in all age groups.

CONCLUSIONS

This retrospective analysis shows that patients vaccinated against COVID-19 demonstrated trends of reduced hospitalisations and premature mortality in patients with CVD, solid malignancy or CPD as a single comorbidity.

摘要

目的

本研究聚焦于保加利亚的患者队列,这些患者患有单一记录的慢性合并症——心血管疾病、肿瘤疾病或慢性肺部疾病(CPD),并比较了按性别和年龄组分类的在门诊、住院和重症监护病房(ICU)环境下完全接种疫苗和未接种疫苗人群的结局,这是在国家层面上进行的。

设计

回顾性分析

设置、参与者和结局测量:2020 年 3 月至 2022 年 4 月期间,我们在国家层面上使用卫生部于 2020 年 3 月推出的联合信息门户的数据,对总共 1126946 例确诊的 COVID-19 患者进行了回顾性分析。

结果

在所有确诊的 247441 例住院 COVID-19 病例中,67723 例(27.3%)有记录的心血管疾病(CVD),2140 例(0.9%)有明确的实体恶性肿瘤(无论分期如何),3243 例(1.3%)有明确的 CPD 作为唯一的慢性疾病。每个亚组的累积死亡人数为 10165 例(住院=5812 例和 ICU=4353 例);4.0%接种疫苗(410/10165,p<0.001),344 例(住院=196 例和 ICU=148 例),4.9%接种疫苗(17/344,p<0.001),494 例(住院=287 例和 ICU=207 例)和 5.2%接种疫苗(26/494,p<0.001)。接种疫苗的队列在门诊、住院和住院及 ICU 相关死亡率方面均显示出降低的趋势,差异具有统计学意义(p<0.001),并且 BNT162b2 在所有年龄组中预防死亡率的效果最为显著。

结论

这项回顾性分析表明,在 CVD、实体恶性肿瘤或 CPD 作为单一合并症的患者中,接种 COVID-19 疫苗的患者表现出住院和过早死亡减少的趋势。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/778d/10401219/89b1d056bbbb/bmjopen-2022-068431f05.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/778d/10401219/9a18061ffaa3/bmjopen-2022-068431f01.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/778d/10401219/0af95bfe5892/bmjopen-2022-068431f02.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/778d/10401219/a1aae53e7136/bmjopen-2022-068431f03.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/778d/10401219/70cff68d499d/bmjopen-2022-068431f04.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/778d/10401219/89b1d056bbbb/bmjopen-2022-068431f05.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/778d/10401219/9a18061ffaa3/bmjopen-2022-068431f01.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/778d/10401219/0af95bfe5892/bmjopen-2022-068431f02.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/778d/10401219/a1aae53e7136/bmjopen-2022-068431f03.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/778d/10401219/70cff68d499d/bmjopen-2022-068431f04.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/778d/10401219/89b1d056bbbb/bmjopen-2022-068431f05.jpg

相似文献

1
Nationwide analysis of the impact of COVID-19 in patients with a cardiovascular, oncological or chronic pulmonary disease in the context of an Eastern European country with a low vaccination rate, Bulgaria: March 2020-April 2022.在一个疫苗接种率较低的东欧国家保加利亚,对心血管、肿瘤或慢性肺部疾病患者在 COVID-19 背景下的全国范围分析:2020 年 3 月至 2022 年 4 月。
BMJ Open. 2023 Aug 2;13(8):e068431. doi: 10.1136/bmjopen-2022-068431.
2
Infections, hospitalisations, and deaths averted via a nationwide vaccination campaign using the Pfizer-BioNTech BNT162b2 mRNA COVID-19 vaccine in Israel: a retrospective surveillance study.在以色列全国范围内使用辉瑞-生物科技公司的 BNT162b2 mRNA COVID-19 疫苗进行疫苗接种运动,以预防感染、住院和死亡:一项回顾性监测研究。
Lancet Infect Dis. 2022 Mar;22(3):357-366. doi: 10.1016/S1473-3099(21)00566-1. Epub 2021 Sep 22.
3
Protection from previous natural infection compared with mRNA vaccination against SARS-CoV-2 infection and severe COVID-19 in Qatar: a retrospective cohort study.与 SARS-CoV-2 感染和卡塔尔严重 COVID-19 相比,先前自然感染的保护作用:一项回顾性队列研究。
Lancet Microbe. 2022 Dec;3(12):e944-e955. doi: 10.1016/S2666-5247(22)00287-7. Epub 2022 Nov 11.
4
Effectiveness of BNT162b2 vaccine against SARS-CoV-2 infection and severe COVID-19 in children aged 5-11 years in Italy: a retrospective analysis of January-April, 2022.意大利 2022 年 1 月至 4 月的一项回顾性分析:BNT162b2 疫苗在 5-11 岁儿童中预防 SARS-CoV-2 感染和 COVID-19 重症的效果。
Lancet. 2022 Jul 9;400(10346):97-103. doi: 10.1016/S0140-6736(22)01185-0. Epub 2022 Jul 1.
5
Comparative Study of Vaccinated and Unvaccinated Hospitalised Patients: A Retrospective Population Study of 500 Hospitalised Patients with SARS-CoV-2 Infection in a Spanish Population of 220,000 Inhabitants.接种疫苗和未接种疫苗的住院患者比较研究:西班牙 22 万居民中 500 名住院 SARS-CoV-2 感染患者的回顾性人群研究。
Viruses. 2022 Oct 17;14(10):2284. doi: 10.3390/v14102284.
6
Covid-19 vaccination programme effectiveness against SARS-CoV-2 related infections, hospital admissions and deaths in the Apulia region of Italy: a one-year retrospective cohort study.意大利普利亚地区新冠疫苗接种计划对 SARS-CoV-2 相关感染、住院和死亡的有效性:一项为期一年的回顾性队列研究。
Sci Rep. 2022 Nov 3;12(1):18597. doi: 10.1038/s41598-022-23235-4.
7
BNT162b2 and ChAdOx1 nCoV-19 vaccinations, incidence of SARS-CoV-2 infections and COVID-19 hospitalisations in Scotland in the Delta era.BNT162b2 和 ChAdOx1 nCoV-19 疫苗接种、苏格兰在 Delta 时代 SARS-CoV-2 感染和 COVID-19 住院的发生率。
J Glob Health. 2022 Mar 26;12:05008. doi: 10.7189/jogh.12.05008. eCollection 2022.
8
Length of hospital stay and risk of intensive care admission and in-hospital death among COVID-19 patients in Norway: a register-based cohort study comparing patients fully vaccinated with an mRNA vaccine to unvaccinated patients.挪威 COVID-19 患者住院时间与入住重症监护病房和院内死亡风险的关系:一项基于登记的队列研究,比较了完全接种 mRNA 疫苗的患者与未接种疫苗的患者。
Clin Microbiol Infect. 2022 Jun;28(6):871-878. doi: 10.1016/j.cmi.2022.01.033. Epub 2022 Feb 25.
9
Association of BNT162b2 mRNA and mRNA-1273 Vaccines With COVID-19 Infection and Hospitalization Among Patients With Cirrhosis.BNT162b2 mRNA 疫苗和 mRNA-1273 疫苗与肝硬化患者 COVID-19 感染和住院的关联。
JAMA Intern Med. 2021 Oct 1;181(10):1306-1314. doi: 10.1001/jamainternmed.2021.4325.
10
Association Between Vaccination With BNT162b2 and Incidence of Symptomatic and Asymptomatic SARS-CoV-2 Infections Among Health Care Workers.BNT162b2 疫苗接种与医护人员中出现有症状和无症状 SARS-CoV-2 感染的相关性。
JAMA. 2021 Jun 22;325(24):2457-2465. doi: 10.1001/jama.2021.7152.

引用本文的文献

1
Comparative Effectiveness of mRNA-1273 and BNT162b2 COVID-19 Vaccines Among Adults with Underlying Medical Conditions: Systematic Literature Review and Pairwise Meta-Analysis Using GRADE.mRNA-1273和BNT162b2新冠疫苗在有基础疾病的成年人中的比较效果:使用GRADE的系统文献综述和成对荟萃分析
Adv Ther. 2025 May;42(5):2040-2077. doi: 10.1007/s12325-025-03117-7. Epub 2025 Mar 10.
2
SARS-CoV-2 Infection of the Central Nervous System: A Case Report.新型冠状病毒2型感染中枢神经系统:一例报告
Viruses. 2024 Dec 21;16(12):1962. doi: 10.3390/v16121962.
3
Relative Risk of Death in Bulgarian Cancer Patients during the Initial Waves of the COVID-19 Pandemic.

本文引用的文献

1
Comorbidities and covid-19.合并症与新冠病毒病
BMJ. 2022 Jun 15;377:o1431. doi: 10.1136/bmj.o1431.
2
Assessing the burden of COVID-19 in developing countries: systematic review, meta-analysis and public policy implications.评估发展中国家的 COVID-19 负担:系统评价、荟萃分析和公共政策影响。
BMJ Glob Health. 2022 May;7(5). doi: 10.1136/bmjgh-2022-008477.
3
A web-based app to provide personalized recommendations for COVID-19.一款用于提供新冠肺炎个性化推荐的基于网络的应用程序。
保加利亚癌症患者在新冠疫情最初几波期间的死亡相对风险
Healthcare (Basel). 2023 Sep 20;11(18):2594. doi: 10.3390/healthcare11182594.
Nat Med. 2022 Jun;28(6):1105-1106. doi: 10.1038/s41591-022-01797-0.
4
Long-term Immunogenicity of BNT162b2 Vaccine in Patients With Solid Tumors.BNT162b2疫苗在实体瘤患者中的长期免疫原性
JAMA Oncol. 2022 Jun 1;8(6):1-2. doi: 10.1001/jamaoncol.2022.1467.
5
SARS-CoV-2: from herd immunity to hybrid immunity.SARS-CoV-2:从群体免疫到混合免疫。
Nat Rev Immunol. 2022 Jun;22(6):333-334. doi: 10.1038/s41577-022-00725-0.
6
COVID-19 vaccine hesitancy.新冠疫苗犹豫
Nat Rev Nephrol. 2022 Jul;18(7):409-410. doi: 10.1038/s41581-022-00571-2.
7
COVID-19 vaccine waning and effectiveness and side-effects of boosters: a prospective community study from the ZOE COVID Study.COVID-19 疫苗效力下降和加强针的有效性和副作用:来自 ZOE COVID 研究的一项前瞻性社区研究。
Lancet Infect Dis. 2022 Jul;22(7):1002-1010. doi: 10.1016/S1473-3099(22)00146-3. Epub 2022 Apr 8.
8
Estimating excess mortality due to the COVID-19 pandemic: a systematic analysis of COVID-19-related mortality, 2020-21.估算2019冠状病毒病大流行造成的超额死亡率:2020 - 2021年与2019冠状病毒病相关死亡率的系统分析
Lancet. 2022 Apr 16;399(10334):1513-1536. doi: 10.1016/S0140-6736(21)02796-3. Epub 2022 Mar 10.
9
A comparison of health system responses to COVID-19 in Bulgaria, Croatia and Romania in 2020.2020 年保加利亚、克罗地亚和罗马尼亚应对 COVID-19 疫情的卫生系统比较。
Health Policy. 2022 May;126(5):456-464. doi: 10.1016/j.healthpol.2022.02.003. Epub 2022 Feb 17.
10
Pandemic preparedness and COVID-19: an exploratory analysis of infection and fatality rates, and contextual factors associated with preparedness in 177 countries, from Jan 1, 2020, to Sept 30, 2021.大流行防范与新冠疫情:对2020年1月1日至2021年9月30日期间177个国家的感染率、死亡率以及与防范相关的背景因素进行的探索性分析。
Lancet. 2022 Apr 16;399(10334):1489-1512. doi: 10.1016/S0140-6736(22)00172-6. Epub 2022 Feb 1.